The BLog

Exciting news in the world of regenerative medicine: The FDA has officially approved RYONCIL®, the first mesenchymal stromal cell (MSC) therapy. This groundbreaking treatment is designed to help children with steroid-refractory acute graft-versus-host disease (SR-aGVHD), a serious complication following stem cell transplants. While this approval is focused on a specific condition, it signals a major […]